In clinical trials, certain newer diabetes medications have been shown to reduce CVD events in addition to lowering blood sugar in diabetics at high risk for CVD. The GLP-1 receptor agonists liraglutide (Victoza, Saxenda) and semaglutide (Ozempic), and the SGLT2 inhibitors empagliflozin (Jardiance) and canagliflozin (Invokana) have been shown to be superior to placebo at preventing CVD death, heart attack, stroke and heart failure in patients with known CVD. Both drug classes are associated with lower risk of symptomatic low blood sugar levels (hypoglycemia) and weight loss.
To continue reading this article or issue you must be a paid subscriber.
Sign in
